TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00939003

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: 40 mg every other week up to Week 12

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo every other week up to Week 12

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Open-label Adalimumab
Description: 40 mg every other week, Week 12 through Week 156
Study: NCT00951925

Intervention type: OTHER
Intervention: Bone Marrow Aspirate Draw
Description: 5cc of Bone Marrow Aspirate will be drawn
Study: NCT03884439

Intervention type: DRUG
Intervention: Infliximab [infliximab biosimilar 3]
Description: \<Crohn's disease\> The usual dose is 5 mg as Infliximab \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have reduced effects. At an increased dose, the dose may be adjusted to 10 mg for every kg of body weight. At a reduced dosing interval, the dose of 5 mg for every kg of body weight may be given at the minimum dosing interval of 4 weeks. \<Ulcerative colitis\> The usual dose is 5 mg as Infliximab \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter.
Study: NCT03476460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral sodium chloride
Description: Patients will receive capsules of sodium chloride and free water ingestion (for each capsule of sodium chloride, with 250 ml of water, assuring a minimum ingestion of 750 ml of water) in the 48 hours prior contrast injection. Patients will take capsules of sodium chloride at a dose of 100 mg/kg during 48 hours previous the injection of contrast (48, 40, 32, 24, 16, and 8 hours), at the moment of contrast injection and 12 hours after the injection of contrast.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous sodium chloride
Description: Patients will receive at hospital 3 ml/Kg of sodium chloride 0.9%, one hour previous contrast injection and 2 ml/kg during the 4 hours after contrast injection.
Study: NCT02592161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks~Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment)~Three times a day, oral administration for 24weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Experimental
Description: Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks~Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment)~Three times a day, oral administration for 24weeks
Study: NCT02978586

Intervention type: DEVICE
Intervention: [Ga-68]PSMA PET/MR
Description: All participants will undergo at least 1 baseline \[Ga-68\]PSMA PET/MR. If participants test positive for \[Ga-68\]PSMA tumor uptake, they will under up to 2 additional scans
Study: NCT00118547

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In home monitoring with feedback
Description: Behavioral counseling
Study: NCT03300934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: closed loop glucose control system
Description: Cross over between Closed loop glucose system with DANA pump, Navigator II CGM and Cambridge AP algorithm FD2A, versus usual CSII pump treatment
Study: NCT02745899

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cow milk
Description: Ingestion of 240 ml cow milk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cow milk
Description: Ingestion of 240 ml cow milk

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy milk
Description: Ingestion of 240 ml soy milk

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy milk
Description: Ingestion of 240 ml soy milk
Study: NCT04220151

Intervention type: GENETIC
Intervention: DNA methylation
Description: DNA methylation will be measured by real time polymerase chain reaction

Intervention type: GENETIC
Intervention: DNA methylation
Description: DNA methylation will be measured by real time polymerase chain reaction

Intervention type: GENETIC
Intervention: DNA methylation
Description: DNA methylation will be measured by real time polymerase chain reaction
Study: NCT06772922

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: effect of exercise after three months (comparison of the patient with himself)
Study: NCT01041911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Euphorbia tablets
Description: 50 mg, tablet, once daily, 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Euphorbia tablets
Description: 100 mg, tablet, once daily, 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Euphorbia tablets
Description: 200 mg, tablet, 2 tablets of 100 mg Euphorbia prostrata, 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: placebo, tablet, once daily, 14 days
Study: NCT01346098

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticoduodenectomy with pancreatic anastomosis
Description: Standard lymphadenectomy, end-to-side two-layer pancreaticojejunostomy and duodenojejunostomy will be performed. If the pylorus is preserved, so will be the right gastric artery, unless the artery is damaged or hindering adequate gastric mobilization. No prokinetic agent will be administered routinely, but IV metoclopramide will given on demand (10 mg , three times daily). Prophylaxis will consist of octreotide (0,1 mg three times daily from day 0 to 7), low molecular weight heparin and a single dose of antibiotic (cefazolin 2 g). Early postoperative analgesia will be achieved by epidural or, when contraindicated, patient-controlled analgesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total pancreatectomy with islet autotransplantation
Description: If the patient will be assigned to this group, the surgeon will complete the pancreatectomy preserving the spleen. The body and tail of the pancreas will be sent to the islet isolation facility. Islets will be isolated and purified according to the automated method described by Ricordi. The resulting islet tissue will be suspended in a cold isotonic saline solution and infused into the portal vein during the next 24h.
Study: NCT03247309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA201 Product
Description: The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IMADetect®
Description: IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials with investigational IMA201 therapy. IMADetect® is intended for investigational use only.
Study: NCT01853865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instruction in self-referral
Study: NCT02499562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydronidone
Description: The investigational products in the test groups and control group shall be orally taken 30 minutes before meals for 52 continuous weeks. There are respectively 60 cases in the test group I, II, III and the control group, totally 240 cases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydronidone
Description: The investigational products in the test groups and control group shall be orally taken 30 minutes before meals for 52 continuous weeks. There are respectively 60 cases in the test group I, II, III and the control group, totally 240 cases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydronidone
Description: The investigational products in the test groups and control group shall be orally taken 30 minutes before meals for 52 continuous weeks. There are respectively 60 cases in the test group I, II, III and the control group, totally 240 cases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Study: NCT05126693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin treatment combined with a post-BoNT intensive physical therapy period guided by individualized treatment goals.
Description: BoNT treatment combined with a follow-up period of intensive physical therapy of 8-10 weeks. During this intensive physical therapy post BoNT injections, the children in the intervention group will work on individualized treatment goals, which will be defined based on the baseline measurements during a multidisciplinary discussion with the treating physician (planned prior to the BoNT injections).
Study: NCT01124253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human endostatin
Description: recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: recombinant human endostatin
Description: recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
Study: NCT02854462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Language comprehension intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counting intervention
Study: NCT03188822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioabsorbable steroid releasing sinus implant
Description: After completion of indicated frontal sinus surgery, patients will have a bioabsorbable steroid releasing implant placed in the frontal sinus opening, which will remain in place for 14 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioabsorbable nasal dressing impregnated with steroid
Description: After completion of indicated frontal sinus surgery, patients will have a bioabsorbable nasal dressing impregnated with steroid placed in the frontal sinus opening, which will remain in place for 14 days.
Study: NCT01260129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: Silodosin 8 mg orally, once daily after morning meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: Silodosin 4 mg orally, twice daily after morning and evening meal
Study: NCT00643175

Intervention type: BEHAVIORAL
Intervention: Automated follow up
Description: Treatment of osteoporosis after hip fracture is also being targeted as a future hospital quality assessment measure. Hospitals which have no plan in place to address osteoporosis treatment after hip fracture may be cited, and may have medicare money withheld. The goal of the study is to create an automated in-patient endocrinology consultation for osteoporotic hip fractures. We plan to gather patient data in a prospective manner including the endocrinologist recommendations, adherence to medical therapy after discharge, and future fracture rates. Planned interventions include only appropriate medical therapy for osteoporosis, DEXA bone scanning, and regularly scheduled telephone follow-up.
Study: NCT03042689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib will be administered on a 28 day cycle Treatment will be administered on outpatient basis at a pre-determine dosage.
Study: NCT04290104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1gr oral ampicillin/sulbactam group
Description: Group prescribed 1 g oral ampicillin/sulbactam 2 times a day.
Study: NCT02320175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient and Family Centered I-PASS
Description: Patient and Family-Centered I-PASS is a bundle of communication interventions to improve the quality of information exchange between physicians, nurses, and families, and to better integrate families into all aspects of daily decision making in hospitals. The intervention included a health literacy-informed, structured communication framework for family-centered rounds; written rounds summaries for families; a training and learning program; and strategies to support teamwork and implementation.
Study: NCT02910232

Intervention type: DEVICE
Intervention: bone void filler
Description: Bone void filler device prepared from porous starch-hydroxyapatite composites for bone regeneration
Study: NCT03136198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LUS-guided strategy-of-care
Description: For patients randomized to the strategy-of-care arm, the LUS guided protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~1. IV furosemide (unless already given): 2x single oral dose if on chronic therapy or 20-40 mg if diuretic naive.~2. Optional therapies: non-invasive ventilation, vasodilators (SL, topical, or IV)~3. Reassessment every 2 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Patients will receive usual AHF care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Loop Diuretic
Description: IV loop diuretic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Loop Diuretic
Description: IV loop diuretic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasodilator
Description: IV, topical, or SL Vasodilator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vasodilator
Description: IV, topical, or SL Vasodilator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive Ventilation (NIV)
Description: Face, mouth, or nasal mask applied to provide positive pressure ventilation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non invasive Ventilation (NIV)
Description: Face, mouth, or nasal mask applied to provide positive pressure ventilation
Study: NCT01503788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: participants will be given Midazolam IV 10-5 minutes prior to diagnostic lumbar puncture
Study: NCT04546646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic Band Exercises
Description: Resistance exercise will be performed using theraband. The color of the band denotes the degree of elasticity and resistance level(yellow , red ,green ,blue, black or silver).Exercise load in terms of individual yielding elasticity (band color) in resistance training will set at a level that a patient perceived as somewhat hard, which is equivalent to a 13-grade rating (moderate intensity exercise) on the RPE, According to American College of Sports Medicine. For each exercise movement 3 sets of 10 repetitions of gentle concentric and eccentric contractions through the full range of motion will be slowly performed using a yellow Thera band initially. The exercise intensity will be increased when the patient is able to achieve a perceived yield strength corresponding to a 13- grade rating on the RPE scale.
Study: NCT01759914

Intervention type: DRUG
Intervention: Potent topical steroid

Intervention type: DRUG
Intervention: Superpotent topical steroid
Study: NCT01963468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early language intervention
Description: Parents will practice the specific set of strategies (visual, interactive, tactile, responsive) during sessions that occur weekly and last 1 hour for a total of 26 sessions, over 6 months. Each session will include four segments: (a) the therapist will review the intervention strategies taught in the workshop (10 min), (b) the therapist will model the intervention strategy with the child (10 min), (c) the parent will practice the strategy with her child with coaching from the therapist across four different routines and activities of the parent's choice (30 min), and (d) the therapist will provide feedback to the parent, summarize the session, and answer the parent's questions (10 min).
Study: NCT00346437

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Ad5FGF-4 vs. Placebo
Description: Intracoronary infusion

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Ad5FGF-4 vs. Placebo
Description: Intracoronary infusion

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Ad5FGF-4 vs. Placebo
Description: Intracoronary infusion
Study: NCT00514696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCS-100
Description: GCS-100: 160 mg/m2 IV (in the vein) Study Days 1-5 of each 21-day cycle
Study: NCT03073759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dTCS
Description: Direct current (DC) (maximum of 2 mA) stimulation delivered through surface electrodes. One electrode will be positioned above the left or right primary motor cortex, the other electrode over the forehead.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: The device will administer a sham.
Study: NCT03754543

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Labeled iron salt Fe54
Description: Ferrous fumarate enriched with Fe 54 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Labeled iron salt Fe54
Description: Ferrous fumarate enriched with Fe 54 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Labeled iron salt Fe57
Description: Ferrous fumarate enriched with Fe 57 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Labeled iron salt Fe57
Description: Ferrous fumarate enriched with Fe 57 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Labeled iron salt Fe58
Description: Ferrous bisglycinate enriched with Fe 58 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
Study: NCT04285411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accuracy of the VitalDetect™ pulse oximetry system
Description: The purpose of this study was to validate the SpO2 accuracy of the VitalDetect™ pulse oximetry system during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry. It was expected that the Accuracy Root Mean Square (ARMS) performance of the oximetry system would meet the required specification of ARMS of 3.0% or less.
Study: NCT03197129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sensory adapted waiting room
Description: The SADE waiting room: a small waiting room (2.5mx2.5m) inside the clinic with 6 seats. A lighting column that children can touch and climb on. Auditory stimuli include rhythmic music, which is heard via loudspeakers.
Study: NCT02760888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Women will receive a oral Tramadol 100mg 1 hour before the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Women will receive oral Diclofenac 100mg 1 hour before the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Women will receive a Placebo 1 hour before the procedure
Study: NCT04744623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP
Description: 10 patients suffering from MMP were selected after complete diagnosis based on their clinical diagnosis and immunopathologic findings of IgG, IgA, and/or C3 targeting skin basement membranes with a linear deposition pattern refered from dermatology department. These patient were treated using large dose of prednisone 60mg daily plus intrational injection of Triamcinolone Acetonide every week until no further improvement of the lesion occurred (stage I) then the prednisolone is withdrawn gradually and substituted with using 1 g of MMF plus 50 mg dapsone till the lowest dose of prednisone could be reached (stage II).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP
Description: 10 patients suffering from MMP were selected after complete diagnosis based on their clinical diagnosis and immunopathologic findings of IgG, IgA, and/or C3 targeting skin basement membranes with a linear deposition pattern refered from dermatology department. These patient were treated using large dose of prednisone 60mg daily plus intrational injection of Triamcinolone Acetonide every week until no further improvement of the lesion occurred (stage I) then the prednisolone is withdrawn gradually and substituted with using 1 g of MMF plus 50 mg dapsone till the lowest dose of prednisone could be reached (stage II).
Study: NCT02685930

Intervention type: BEHAVIORAL
Intervention: Antibiotic de-escalation by ICU stewardship team with decreased exposure to broad spectrum antibiotics and shorter duration of therapy
Description: ICU stewardship team will provide recommendations to the ICU team regarding antibiotic de-escalation and duration of therapy in attempts of improving antibiotic stewardship practices without compromising patient outcomes.Recommendations will be based on patient showing clinical improvement combined with microbial culture data.
Study: NCT04732234

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superior Hypogastric Plexus Block
Description: Pre operative ultrasound guided superior hypogastric plexus block in pelvic surgeries using a curvilinear probe below umbalicus with needle in plane technique to reach the plexus in front of L5 vertebra

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Superior Hypogastric Plexus Block
Description: Pre operative ultrasound guided superior hypogastric plexus block in pelvic surgeries using a curvilinear probe below umbalicus with needle in plane technique to reach the plexus in front of L5 vertebra
Study: NCT01022606

Intervention type: OTHER
Group type: OTHER
Intervention: Arterial sampling
Description: Arterial pO2 (ABL5) Body Temperature (Vitalsens Cortemp) tcpO2 TCM400
Study: NCT02339636

Intervention type: OTHER
Intervention: PDUS examination

Intervention type: OTHER
Intervention: PDUS examination